Recordati Industria Chimica e Farmaceutica - RCDTF Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$51.60
+0 (0.00%)

This chart shows the closing price for RCDTF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Recordati Industria Chimica e Farmaceutica Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RCDTF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RCDTF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Recordati Industria Chimica e Farmaceutica in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $51.60.

This chart shows the closing price for RCDTF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Recordati Industria Chimica e Farmaceutica. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/31/2023Royal Bank of CanadaInitiated CoverageSector Perform
2/17/2023BarclaysDowngradeEqual Weight ➝ Underweight
1/3/2023JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
11/2/2022BarclaysLower Target€44.00 ➝ €40.00
7/29/2022Oddo BhfUpgradeUnderperform ➝ Neutral€42.00
2/28/2022Deutsche Bank AktiengesellschaftLower TargetHold ➝ Hold€47.00 ➝ €44.00
11/2/2021BarclaysReiterated RatingEqual Weight
11/1/2021JPMorgan Chase & Co.Reiterated RatingNeutral
9/17/2021BarclaysInitiated CoverageEqual Weight
7/30/2021Oddo BhfDowngradeNeutral ➝ Underperform
6/25/2021JPMorgan Chase & Co.Initiated CoverageNeutral
4/20/2021Deutsche Bank AktiengesellschaftInitiated CoverageHold
10/30/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral
8/4/2020Jefferies Financial GroupDowngradeBuy ➝ Hold
(Data available from 6/19/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/22/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/22/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/20/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/19/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Recordati Industria Chimica e Farmaceutica logo
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.
Read More

Today's Range

Now: $51.60
Low: $51.60
High: $51.60

50 Day Range

MA: $51.60
Low: $51.60
High: $51.60

52 Week Range

Now: $51.60
Low: $51.60
High: $51.98

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.33

Frequently Asked Questions

What sell-side analysts currently cover shares of Recordati Industria Chimica e Farmaceutica?

The following equities research analysts have issued research reports on Recordati Industria Chimica e Farmaceutica in the last year:
View the latest analyst ratings for RCDTF.

What is the current price target for Recordati Industria Chimica e Farmaceutica?

0 Wall Street analysts have set twelve-month price targets for Recordati Industria Chimica e Farmaceutica in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Recordati Industria Chimica e Farmaceutica in the next year.
View the latest price targets for RCDTF.

What is the current consensus analyst rating for Recordati Industria Chimica e Farmaceutica?

Recordati Industria Chimica e Farmaceutica currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for RCDTF.

What other companies compete with Recordati Industria Chimica e Farmaceutica?

Other companies that are similar to Recordati Industria Chimica e Farmaceutica include Allkem, Amadeus IT Group, Amplifon, ANA and ASSA ABLOY AB (publ). Learn More about companies similar to Recordati Industria Chimica e Farmaceutica.

How do I contact Recordati Industria Chimica e Farmaceutica's investor relations team?

Recordati Industria Chimica e Farmaceutica's physical mailing address is Via Matteo Civitali 1, Milano L6, 20148. The company's listed phone number is 390-248-7871 and its investor relations email address is [email protected]. The official website for Recordati Industria Chimica e Farmaceutica is www.recordati.com. Learn More about contacing Recordati Industria Chimica e Farmaceutica investor relations.